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Abstract
Ubiquitin ligase Atrogin1/Muscle Atrophy F-box (MAFbx) up-regulation is required for skeletal muscle atrophy but
substrates and function during the atrophic process are poorly known. The transcription factor MyoD controls myogenic
stem cell function and differentiation, and seems necessary to maintain the differentiated phenotype of adult fast skeletal
muscle fibres. We previously showed that MAFbx mediates MyoD proteolysis in vitro. Here we present evidence that MAFbx
targets MyoD for degradation in several models of skeletal muscle atrophy. In cultured myotubes undergoing atrophy,
MAFbx expression increases, leading to a cytoplasmic-nuclear shuttling of MAFbx and a selective suppression of MyoD.
Conversely, transfection of myotubes with sh-RNA-mediated MAFbx gene silencing (shRNAi) inhibited MyoD proteolysis
linked to atrophy. Furthermore, overexpression of a mutant MyoDK133R lacking MAFbx-mediated ubiquitination prevents
atrophy of mouse primary myotubes and skeletal muscle fibres in vivo. Regarding the complex role of MyoD in adult skeletal
muscle plasticity and homeostasis, its rapid suppression by MAFbx seems to be a major event leading to skeletal muscle
wasting. Our results point out MyoD as the second MAFbx skeletal muscle target by which powerful therapies could be
developed.
Citation: Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP, et al. (2009) Inhibition of Atrogin-1/MAFbx Mediated MyoD Proteolysis
Prevents Skeletal Muscle Atrophy In Vivo. PLoS ONE 4(3): e4973. doi:10.1371/journal.pone.0004973
Editor: Gianni Parise, McMaster University, Canada
Received December 19, 2008; Accepted February 27, 2009; Published March 25, 2009
Copyright:  2009 Lagirand-Cantaloube et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Association Franc ¸aise contre les Myopathies (AFM), the department PHASE from INRA and the Institut
National de la Sante ´ et de la Recherche Me ´dicale (INSERM). J. Lagirand-Cantaloube held a graduate fellowship from the Ministe `re de la Recherche et de la
Technologie (MRT) and an AFM fellowship. Mr. A. Csibi holds a graduate AFM and INRA fellowships. The funders had no role in study design, data collectiona n d
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: leibovs@supagro.inra.fr
¤ Current address: IFR122, CNRS UMR5237, Montpellier, France
Introduction
Skeletal muscle atrophy is characterized by an increase in
proteolysis, particularly via the ATP-dependent ubiquitin-protea-
some pathway [1]. One of the proteins induced most dramatically
in numerous models of atrophy is the muscle-specific F-box
MAFbx [2,3] that associates with Skp1, Cul1 and Roc1 to form an
SCF-type ubiquitin ligase [4,5]. Overexpression of MAFbx in
skeletal myotubes leads to atrophy, whereas knockdown of MAFbx
in mice leads to significant resistance to skeletal muscle
denervation atrophy [2]. Furthermore, F-box proteins confer
SCF specificity by directly interacting with the substrate and there
are increasing evidence about MAFbx participation in a muscle-
specific ubiquitin ligase complex leading to negative regulation of
muscle cell size [6,7]. However, the mechanisms by which MAFbx
contributes to atrophy remain unclear. Recently, we have shown
that overexpression of MAFbx in proliferating myoblasts antag-
onizes differentiation by inducing MyoD degradation [8]. MyoD is
a muscle-specific transcription factor that induces both the
withdrawal from the cell cycle and the activation of muscle
specific genes expression crucial for skeletal muscle differentiation
process engagement [9–11]. MyoD is also essential for myogenic
stem cell function in adult skeletal muscle [12]. Moreover, MyoD
is normally expressed in adult fibres where its protein levels tend to
increase with development and remain relatively constant during
aging in vivo [13,14]. In muscle fibrenuclei, MyoD seems also
required to maintain aging muscle homeostasis and plays a role in
skeletal muscle plasticity in response to hypertrophic or denerva-
tion stimuli [13,15,16]. Therefore, in atrophic conditions, MAFbx-
dependent proteolysis of MyoD could constitute a major event to
suppress muscle homeostasis. To address this problem, in the
present work we have used various in cellulo and in vivo muscle
atrophy models to examine the effects on MyoD degradation
during the atrophic process. we present evidence that MyoD is
targeted by Atrogin1/MAFbx (MAFbx) in skeletal muscle atrophy.
In cultured myotubes undergoing atrophy, the expression of
MAFbx increases, leading to a cytoplasmic-nuclear shuttling of
MAFbx and degradation of MyoD. Among the four MRFs, MyoD
was selectively affected as confirmed by MyoD over-ubiquitina-
tion. Conversely, transfection of myotubes undergoing atrophy
with shRNA-mediated MAFbx gene silencing (shRNAi) prevented
MyoD degradation. Finally, overexpression of a MyoD mutant
(K133R) lacking MAFbx-mediated ubiquitination, not only
reduced starvation-induced muscle atrophy in mouse primary
cultures of myotubes and in mice but lead to a hypertrophy in
control muscle. These results suggest that the targeting of MyoD
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4973by MAFbx may be a major event to suppress the complex role of
MyoD in plasticity and homeostasis in skeletal muscle. Moreover,
the maintain of MyoDK133R in muscle undergoing atrophy has a
protective effect against further wasting. MyoD K133R represents
a new pharmacological target to limit muscle atrophy, in a
profilatic or curative perspective.
Results
MyoD but not the others MRFs interacts with MAFbx
MAFbx contains two potential nuclear localization signals
which both are conserved between human, rat and mouse species
[3,8] suggesting that during muscle atrophy MAFbx might
ubiquitinate muscle-specific transcription factors or nuclear
proteins involved in muscle growth. Indeed, we provided evidence
that ectopically expressed MAFbx interacts with MyoD but not
Myf5 in myoblasts [8]. This prompted us to test the interaction of
MAFbx with the two other muscle specific transcription factors
myogenin and MRF4. We performed co-immunoprecipitation
experiments. 10T1/2 cells were co-transfected with HA-tagged
MyoD, myogenin, MRF4 and Flag-MAFbx expression constructs.
Cell extracts were subjected to immunoprecipitation with anti-Flag
antibodies, followed by immunoblotting analysis with anti-HA
antibodies. MyoD but neither myogenin nor MRF4 coimmuno-
precipitated with MAFbx (Supplementary data Fig S1). These data
show that among the four MRFs, MyoD is the only one that
interacts with MAFbx.
Increasing nuclear localization of MAFbx in C2C12
myotubes that undergo atrophy
Overexpression of MAFbx in proliferating myoblasts antago-
nizes differentiation, inducing nuclear MyoD degradation and
preventing muscle-specific-gene activation [8]. MAFbx has also
been suggested to interact with cytoplasmic proteins such as
calcineurin A and a-actinin-2 at the Z-disc in cardiomyocytes [17].
Altogether these data prompted us to investigate the cellular
localization of MAFbx in skeletal muscle atrophy conditions. As
food deprivation leads to rapid muscle wasting and increases
MAFbx mRNA expression in vivo and in C2C12 cultures [6,7] we
repeated this experiment to follow MyoD immuno-staining. In
control myotubes, MyoD showed a typical nuclear staining while
low levels of cytoplasmic MAFbx were observed (Fig. 1, a–e). After
6 hours of starvation, myotubes showed a 50–60% decrease in
diameter [7], a loss of myonuclei and a nuclear localization of
MAFbx. In these myotubes MyoD levels were reduced (Fig. 1, f–j).
Supplying nutrients and serum for 15 h reversed the process. This
was illustrated by the cytoplasmic relocalization of MAFbx and by
high levels of nuclear MyoD as in control myotubes (Fig. 1, k–o).
These observations suggest that MAFbx nuclear translocation is
tightly linked to MyoD degradation in muscle cells undergoing
atrophy. This hypothesis was strengthened by the fact that ectopic
expression of MAFbx-GFP into C2C12 myotubes revealed
myonuclear accumulation of the fusion protein and an atrophic
phenotype. MyoD staining was lost in these transfected myotubes
while C2C12 myotubes transfected with the empty vector were
unaffected (Fig. 2). These data show that in muscle cells
undergoing atrophy MAFbx is preferentially observed in the
nucleus of muscle cells.
Degradation of MyoD in myotubes undergoing atrophy
MyoD is critical in muscle development and differentiation but
MyoD has recently been shown to increase in muscle fibres with
maturity in mice and is not due to satellite cell activation [14].
Although MyoD is clearly required for efficient muscle repair [12]
the loss of myoD function was shown to lead to failure to maintain
myonuclear density and increased nuclear domain size in fibres
during murine age-related muscle atrophy [14]. We previously
showed that the level of MAFbx protein increased in skeletal
Figure 1. Starvation induces nuclear localization of the MAFbx protein and degradation of MyoD in C2C12 myotubes. C2C12
myotubes at day4 of differentiation were starved by removal of growth medium, amino acids and glucose and were incubated in PBS for 6 h
(Starved). Fresh medium, amino acids and glucose were replaced in the refed culture for 15 h (Refed). Myotubes were fixed and immunostained with
anti-MAFbx polyclonal antibodies and anti-MyoD monoclonal antibodies (5.8A). DNA was stained by DAPI. Myotubes at 4 days of differentiation were
used as control. (Magnifications are6400). Empty arrows indicate a nuclear localization of MAFbx and low levels of MyoD in atrophic myotubes. Full
arrows show MyoD degradation in atrophying myotubes. The right panels show enlarged viewed of the boxed areas.
doi:10.1371/journal.pone.0004973.g001
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tion of the SCF
MAFbx complexes from mouse atrophic muscles
exhibited ubiquitination activity by using MyoD as substrate [8].
The nuclear localization of MAFbx during muscle atrophy and
the loss of MyoD immuno-staining lead us to investigate whether
MyoD could be targeted by MAFbx in response to different
experimental conditions previously shown to induce atrophy of
C2C12 myotubes. Dexamethasone treatment, oxidative stress and
starving cultured C2C12 myotubes undergo atrophy by activating
MAFbx RNA expression [5,18–20]. Indeed treatment with
dexamethasone (DEX), food deprivation (starved) and oxidative
stress (H2O2), all induced a distinct atrophic phenotype charac-
terized by a decrease of,50–60% in myotubes diameter [7] and
an increase of 2–4 fold in MAFbx mRNA and protein levels in
response to these experimental conditions. The changes observed
in starving myotubes were reversed by resupplying nutrients and
serum for 15 hrs (Supplementary data Fig. S2 A to D) [6]. We
determined whether in these experimental conditions MAFbx
affected MyoD expression. We first examined by immunofluores-
cence the presence of MyoD in C2C12 myotubes undergoing
atrophy. Addition of DEX, starvation and /or oxidative stress, all
suppressed MyoD while expression of myogenin was still observed
in C2C12 myotubes undergoing atrophy (Fig. 3A). Western blot
analysis confirmed the degradation of MyoD in C2C12 myotubes
undergoing atrophy. Loss of MyoD by starvation was completely
reversed by supplying serum and nutrients . Western blot data also
revealed that food deprivation was more efficient in MyoD
degradation than the oxidative stress (Fig. 3B). In differentiated
myotubes, the cytokine tumor necrosis alpha (TNF-a) plus
interferon-gamma (IFN-c) signalling is required for NF-kB-
dependent down regulation of MyoD mRNAs and dysfunction
of skeletal myofibrils [21]. To exclude such a mechanism of MyoD
regulation, semi-quantitative RT-PCR experiments were under-
taken. The results showed that increasing concentration of DEX,
Figure 2. MAFbx overepression suppresses MyoD in C2C12 myotubes. A/ C2C12 myotubes were transfected with either empty pcDNA4-
IRES-GFP vector or MAFbx-IRES-GFP. Twenty-four hours later, myotubes were fixed, stained with anti-MyoD (5.8A) and revealed with goat anti-mouse
antibody conjugated to Texas Red. DAPI shows nuclei. Arrows indicate that overexpression of MAFbx (marked by the green GFP) in myotubes
induces an atrophic phenotype and the loss of MyoD staining (absence of red myonuclei). Images of a representative field were obtained by indirect
immunofluorescence microscopy. Magnifications are 6400. B/ Overexpression of the fusion GFP-MAFbx localizes in the nuclei of myotubes and
suppresses MyoD expression. C2C12 myotubes were transfected either with pCMV-GFP expression plasmid (vector) or pCMV-GFP-MAFbx (MAFbx
bound to GFP). Twenty- four hours later, myotubes were fixed and stained with anti-MyoD antibodies as in (A) and with DAPI. Arrows indicate that
overexpression of MAFbx (marked by the green GFP) in the nuclei of myotubes. Images of a representative field were obtained by indirect
immunofluorescence microscopy. Magnifications are 6400.
doi:10.1371/journal.pone.0004973.g002
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PLoS ONE | www.plosone.org 3 March 2009 | Volume 4 | Issue 3 | e4973Figure 3. Specific degradation of MyoD during C2C12 myotubes atrophy. A/ Coimmunostaining analysis of MyoD and myogenin in
myotubes undergoing atrophy. Myotubes at day 4 of differentiation were treated as described in [7]. Myotubes were fixed and stained with anti-
MyoD and anti-myogenin and revealed with goat anti-Rabbit antibody conjugated to Texas Red (c, g, k and l) or with goat anti-mouse antibody
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expression of MyoD mRNAs (Supplementary data Fig. S2, panel
C). Moreover, we used small hairpin RNA interference (shRNAi)
in atrophying C2C12 myotubes to assess the role of MAFbx in
MyoD suppression. Knockdown of MAFbx in these myotubes
prevented by more than 50% the degradation of MyoD while a
control shRNAi did not impair its degradation (Fig. 3C).
Altogether these results show that activation of MAFbx expression
suppresses MyoD in C2C12 myotubes.
Food deprivation and oxidative stress–induced atrophy
increase polyubiquitination by the SCF
MAFbx pathway
and degradation of MyoD by the proteasome
In order to clear up the proteolytic pathway(s) involved in
MyoD degradation during C2C12 myotubes atrophy, we
examined the effect of different proteases inhibitors on the amount
of MyoD in this process. Addition of cystein protease inhibitor
E64, chloroquine, an inhibitor of lysosomal proteolysis, MDL and
I2C (inhibitor 2 of calpains) inhibitors of calpains, or IC3, caspases
inhibitor III, was ineffective in preventing the degradation of
MyoD. On the other hand, treatment with the proteasome
inhibitor MG132 conduced to MyoD protein accumulation in
myotubes undergoing atrophy (Fig. 3, panels D and E). These data
defined the proteasome as the main pathway responsible for
MyoD proteolysis during in cellulo atrophy.
The formation of ubiquitin-protein conjugates involves three
components that participate in a cascade of ubiquitin transfer
reactions: an ubiquitin-activation enzyme (E1), an ubiquitin
conjugating enzyme (E2) and the ubiquitin ligase (E3) that acts
at the last step [22]. The association of MAFbx with the essential
Skp1, Roc1 and Cul1 proteins, specific components of an E3
ubiquitin-ligase (SCF
MAFbx) was previously observed in normal
mice skeletal muscle and increased amounts were found in skeletal
muscle during aging or food deprivation [3,8]. In in vitro
ubiquitination assays, SCF
MAFbx from recombinant baculoviruses
produced in Sf9 cells catalysed the polyubiquitination of MyoD
more effectively than the SCF
MAFbx from normal skeletal muscle
[8]. These data suggest that extend of MyoD ubiquitination is
related to MAFbx expression level. To examine this possibility, we
first employed a reticulocyte extract system wherein in vitro
translated F-box proteins assemble into active SCF [23].
35S–
labeled MyoD was incubated with ATP, ubiquitin, ubiquitin
activating enzyme (E1) in the presence of increasing amount of
MAFbx wt and/or MAFbx-D-F-box (produced in reticulocyte
extracts) and the ubiquitin conjugating (E2) Cdc34. MyoD was
polyubiquitinated in a dose-dependent fashion in the presence of
MAFbx wt. In contrast, the F-box deletion mutant MAFbx-D-F-
box failed to promote polyubiquitination of MyoD (Fig. 4A). Since
food deprivation and the oxidative stress lead to rapid myotubes
atrophy and large increase in MAFbx expression (Supplementary
data , Fig S2), we studied the effects of SCF
MAFbx from cellular
extracts of atrophic myotubes on MyoD ubiquitination. In in vitro
ubiquitination assay, the polyubiquitination of MyoD was
dramatically increased in atrophic myotubes (Fig. 4B). In addition,
in the presence of cellular extracts from starving myotubes, MyoD
showed a higher degree of polyubiquitination than with cellular
extracts from myotubes treated with H202. This increase in MyoD
polyubiquitination probably reflected the fastest degradation of
MyoD in starving myotubes (Fig. 3B).
To confirm in cellulo the effect of MAFbx overexpression on
MyoD polyubiquitination, increasing amounts of expression
vectors encoding MAFbx wt or the mutant MAFbx DF-box were
cotransfected with HA-ubiquitin into C2C12 cells. Cells were
collected, lysed in an SDS-containing buffer and MyoD proteins
were immunoprecipitated with anti-MyoD antibodies. Immuno-
precipitates were then probed with anti-HA to detect ubiquiti-
nated MyoD proteins. In the presence of MAFbx wt, MyoD
showed a dose-dependent polyubiquitination (Fig. 4C, lanes 3 and
5), which was increased by MG132 (lanes 4 and 6) while the
mutant DF-box did not promote ubiquitination of MyoD (lanes 7
and 8). Thus MAFbx induces MyoD polyubiquitination in
atrophic myotubes, a function that requires the F-box motif.
Finally, as polyubiquitination is now known to be involved in
several cellular processes that do not imply proteasomal degrada-
tion, including control of transcription factor activity [24,25], we
examined whether MAFbx increased MyoD turnover in atrophic
myotubes. To this end, we monitored MyoD protein stability after
35S-methionine pulse-labeled of normal and starved myotubes. In
untreated myotubes, the half-life of MyoD was 50–55 minutes, a
value closed to that found in myoblasts and decreased to 20–
30 minutes in starved myotubes (Fig. 4D). A value closed to
30 minutes was also observed for MyoD half-life in H2O2 treated
myotubes (data not shown). These data demonstrate that the rate
of MyoD degradation is increased in myotubes undergoing
atrophy. Altogether these findings indicate that during in cellulo
muscle atrophy, MAFbx overexpression increases MyoD poly-
ubiquitination leading to reduction of its half-life.
Exogenous MyoD delays starvation-induced atrophy in
mouse primary myotubes
In one hand, MyoD has been shown to drive the transcription
of Myosin Heavy Chain (MyHC) [26]. On the other hand, MyHC
is a preferred target of multiple pro-cachectic factors inducing
muscle wasting in vitro and in vivo [27]. Previous works using the
C2C12 culture system demonstrated that TNFa induces an early
expression of MAFbx [20] and in combination with IFNc caused a
pronounced reduction of MyHC without affecting the viability the
myotubes [21,28]. This prompted us to test firstly whether MyHC
conjugated to FITC (d, h, i and p) respectively. DAPI staining shows nuclei (b, f, j and n). Images of a representative field were obtained by indirect
immunofluorescence microscopy. (Magnifications are 6400). B/ Proteins were extracted from treated myotubes and subjected to immunoblot
analysis with specific anti-MyoD and anti-Tropomyosin antibodies respectively. C/ Depletion of MAFbx by shRNAi prevents MyoD degradation in
C2C12 myotubes undergoing atrophy. C2C12 myotubes were transfected by pTER+MAFbx or pTER+control at day 2 of differentiation. Forty-eight
hours later myotubes were treated with H202 (225 mM) or were incubated in PBS (starved) and myotubes were harvested 6 h later. Cell lysates were
prepared and total proteins were subjected to western blot with anti MyoD, anti MAFbx and anti-a-tubulin antibodies. The graph represents
averaged densitometric quantification of the data from three replicate experiments. *P,0.05. D/ Analysis of different cellular proteolysis pathways
inhibitors on MyoD protein level during starvation-induced atrophy. C2C12 myotubes at day 4 of differentiation were starved by removal growth
medium, amino acids and glucose (starved) for 5 h in the presence of DMS0 (lane 2), H2O (lane 3), 30 mM MG132 (lane 4), 30 mM E64 (lane 5), 50 mM
MDL (lane 6) 100 mM chloroquine (lanes 7), 10 mM IC3 (lane 8), 25 mM I2C (lane 9) or refed with fresh medium (lane 10). Cell lysates were prepared
5 h later and 50 mg of total proteins were subjected to western blot with anti–MyoD antibodies (Upper panel). Blot was stripped and reprobed with
anti-Troponin T antibodies. E/ Myotubes at day 3 of differentiation were treated with H202 (9 h) and/or were starved by removal of growth medium
and incubated in PBS (6 h) in the absence (2) of MG132 or in the presence of 30 mM MG132. (+). Fifty micromgramms of total proteins were
subjected to western blot with anti–MyoD and anti-Tropomyosin antibodies.
doi:10.1371/journal.pone.0004973.g003
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atrophy. We observe that in these conditions, MyHC expression
is dramatically decreased whereas no appreciable quantitative loss
occurred with any of the other core myofibrillar proteins such as
Troponin T, Tropomyosins (a and b), a-actin or Myosin Light
Chain 1 (MLC1) (Fig. 5A). Secondly we examined whether
increasing amounts of MyoD are sufficient to oppose to the loss of
MyHC. To test this, we transfected mouse primary myoblasts with
expression vectors encoding HA-tagged MyoDwt or
MyoDK133R, a mutant insensible to SCF
MAFbx polyubiquitina-
tion [8]. Twenty-four hours later, cells were homogenized and
incubated in differentiation medium for three days. Then, the
effects of starving primary cultured myotubes on MyHC protein
expression were studied. In this experiment, transfection by the
empty vector had no effect on MyHC degradation rate. In
contrast, MyoDwt or MyoDK133R overexpression delayed the
starvation-induced atrophy and the loss of MyHC (Fig 5B).
Interestingly, we also noted that the fibres expressing
MyoDK133R displayed a hypertrophic phenotype (Fig. 5C and
8D). Thus, counteracting MyoD degradation protects against in
cellulo muscle atrophy and MyoDK133R mutant resistant to
MAFbx reveals a non-negligible therapeutic interest.
To extend our findings in vivo, we electroporated expression
vectors encoding MyoDwt or MyoDK133R bound to Enhanced
Green Fluorescent Protein (EGFP) into the Tibialis anterior (TA)
muscle of the right hind leg and the EGFP vector into the left hind
leg as an internal control. With this electroporation technique only
muscle fibres express EGFP, satellite cells are not electroporated
(Fig. 6A and L. Schaeffer, personal communication). Fourteen
days after electroporation, mice were either starved for 48 h
(starved) or allowed free access to food (control). In four EGFP,
four MyoDwt-EGFP and four MyoDK133R-EGFP treated
normal TA muscles, cross sectional area was determined in fibres
expressing EGFP (about 200 fibres per muscle). Mean fibre size
was significantly larger in fibres overexpressing MyoDwt
(2430.4+/238.3 mm
2) and MyoDK133R (2692.5+/259 mm
2)
than in fibres overexpressing the control EGFP alone (1908.5+/
237.5 mm
2). The distribution of fibre sizes shifted to the right,
with the range in fibre sizes increasing from 711 to 3530 mm
2 in
control EGFP muscles to 1184 to 3621 mm
2 in muscles
overexpressing MyoDwt and to 867 to 5334 mm
2 with
Figure 4. MAFbx promotes polyubiquitination of MyoD in vitro
and in cellulo. A/ MAFbx promotes polyubiquitination of MyoD in
vitro.
35S-labeled MyoD was incubated with E1, ATP, ubiquitin and
cdc34 (E2) in the presence of increasing amounts of HA-tagged MAFbx
or its F-box deletion mutant produced in rabbit reticulocyte extracts.
Reaction mixtures were separated on SDS-PAGE, followed by autora-
diography (upper panel) and analyzed by Western blotting with anti-HA
antibodies (lower panel). B/ Atrophic myotubes lysates promotes
polyubiquitination of MyoD in vitro. Myotubes at day 4 of differentiation
were treated with H202 (9 h) or were starved for 6 h. Cell lysates were
prepared and 30 mg of total proteins were used for in vitro
ubiquitination assay on equivalent amounts of
35S-labeled MyoD.
Reaction mixtures were separated on SDS-PAGE and followed by
autoradiofluorography. C/ MAFbx increases MyoD ubiquitination in
cellulo. C2C12 myoblastes were transiently transfected with expression
plasmids encoding HA-ubiquitin, Flag-MAFbx wt or the F-box mutant
Flag-MAFbx DF-box. Transfected cells were treated 3 hours with 30 mM
MG132 (+) before harvesting. Cells were lysed in denaturation buffer
containing 0.25%SDS. Aliquots (10%) were analyzed by Western
blotting with anti-HA and anti-Flag antibodies (upper panels). Cell
lysates were then diluted in immunoprecipitation buffer, subjected to
immunoprecipitation with a polyclonal anti–MyoD antibody (C-20), and
analyzed by Western blotting with anti-Flag antibodies and monoclonal
anti-MyoD (5.8A) (lower panels). D/ Increasing instability of MyoD in
atrophic C2C12 myotubes. Myotubes at day 4 of differentiation were
starved for 6 h. Medium was replaced in refed cultures for 15 h.
Myotubes were incubated in methionine-free media for 1 h and then
pulsed with 300 mCi/ml of (
35S)–labeled methionine for 1 h. Following
this incubation, cells were washed with media containing an excess of
cold methionine (10 mM) and chased for the indicated time. Cell lysates
having the same radioactive counts were subjected to immunoprecip-
itation with the anti-MyoD antibodies (C-20). MyoD was analyzed by
SDS-PAGE, followed by autoradiofluorography.
doi:10.1371/journal.pone.0004973.g004
Degradation of MyoD in Atrophy
PLoS ONE | www.plosone.org 6 March 2009 | Volume 4 | Issue 3 | e4973MyoDK133R. Then, the MyoD electroporated fibres in control
mice showed a hypertrophic phenotype notably characterized by a
47% increase in mean cross-section area (CSA) for MyoDK133R
(Fig. 6B). Forty-eight hours starvation reduced CSA by 48.9% in
fibres expressing EGFP alone (975.4+/222.4 mm
2) whereas CSA
from MyoDwt-electroporated fibres showed only an 11.2%
decrease (2216.7+/240.5 mm
2). Of note, hypertrophic fibres
expressing MyoDK133R were completely resistant to food
deprivation (2628.6+/234.3 mm
2) (Fig. 6, B and C). These data
demonstrate for the first time that maintaining MyoD expression
in fibre myonuclei plays a key and unsuspected role in preventing
starvation-induced skeletal muscle atrophy in vivo.
Discussion
We have identified MyoD as the second MAFbx target in
skeletal muscle atrophy. Depending on the atrophic signaling
pathway, MyoD expression seems to be inhibited both at the RNA
and protein levels suggesting that in vivo, MyoD down-regulation is
crucial for muscle loss [8,21,29]. On one hand, whether MAFbx
could participate in the muscle wasting process in vivo by impairing
satellite cells proliferation and differentiation through MyoD
degradation remains to be determined. On the other hand, in fibre
myonuclei, MyoD function is not elucidated. MyoD expression
seems necessary to maintain or to drive muscle-specific gene
transcription like MyHC in response to hypertrophy, denervation
or exercise [15,16]. It has also been reported that when skeletal
muscles undergo atrophy, a subset of myonuclei is lost by apoptosis
even though the rest of the fibre is not affected by this cellular
death. It has been proposed that this process helps muscle fibres to
carefully maintain the cytoplasmic domain controlled by a single
myonucleus [30,31]. Of note, loss of myoD function leads to failure
to maintain this myonuclear density, a mechanism potentially
linked to satellite cells differentiation defects [14]. Moreover
MyoD directly transactivates the cyclin-dependent kinase inhibitor
p21 (p21) and the retinoblastoma protein (Rb), a downstream
target of p21 in vitro. These factors act to regulate cell cycle
withdrawal and antiapoptotic cell death [32]. Hence, MyoD could
also control antiapoptotic pathways inside the fibre to maintain
muscle homeostasis.
In addition, skeletal muscle atrophy is characterized by
enhanced myofibrillar destabilization and proteolysis [33]. How-
ever, to date, MAFbx does not seem to target core skeletal
myofibrillar proteins. While in the cardiomyocytes, MAFbx has
been shown to interact with calcineurin A and a-actinin 2 at the Z-
disc [17], in skeletal muscle cells, MAFbx overexpression did not
modify calcineurin A protein levels nor interact with a-actinin 2
(data not shown). We propose that MAFbx most direct function in
the atrophic process is to act in parallel to myofibrillar proteolysis.
Our results strongly suggest that MAFbx overexpression in
atrophic muscle fibres not only inhibits skeletal muscle protein
translation via eIF3-f proteolysis [7] but also acts through
suppression of MyoD specific transcriptional activity among the
fibre. Impairment of these two pathways is likely to conduce to
muscle fibre shift from anabolism to catabolism. However, if
MAFbx-dependent activation of Foxo transcription factors
discovered in cardiomyocytes [24] is conserved in skeletal muscle
fibres, MAFbx would also play an indirect role on skeletal
myofibrillar proteolysis stimulation.
Figure 5. Overexpression of MyoD delays starvation-induced
atrophy in primary mouse skeletal muscle myotubes. A/ Primary
muscle skeletal myotubes at day 4 of differentiation were starved by
removal growth medium, amino acids and glucose and were incubated
in PBS for 6 h. Cell lysates were prepared and 50 mg of total proteins
were subjected to Western blot analysis to probe for MAFbx, MyoD and
myofibrillar proteins. B/ Primary culture of satellite cells were
transfected with the expression vector encoding HA-MyoDwt and/or
the mutant HA-MyoD K133R as indicated. Twenty-four hours later, cells
were homogenized, and at confluence, cells were placed in differen-
tiation medium. Myotubes at day 4 of differentiation were harvested at
various times as indicated. Cell lysates were prepared and 50 mg of total
proteins were subjected to Western blot with anti–HA antibodies, anti-
MyoD antibodies, anti-MyHC antibodies and anti-Cdk4 antibodies as
internal control of loading. C/ Myotubes were stained with Hoechst
33258 to visualize the nuclei and with anti-HA antibodies to detect
exogenous MyoD expression protein (red) and anti-MyHC antibodies
(green) respectively. Images of a representative field were obtained by
light microscopy (Scale bar 100 mm). D/ Myotubes diameter after MyoD
overexpression in normal and atrophic medium. Experiments were
repeated three times with similar results. Data represent the average
6s.e. of at least 150 myotubes. *P,0.05 between control and MyoDwt
or MyoD K133R overexpressing cells,
#P,0.05 between MyoDwt and
MyoD K133R.
doi:10.1371/journal.pone.0004973.g005
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PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4973The eventual outcome of skeletal muscle atrophy studies is to
develop efficient muscle-specific strategies to prevent and/or slow
down skeletal muscle loss. The new data presented here suggest
that designing MAFbx specific inhibitors that disrupt its
interaction with MyoD or overexpressing MyoDK133R in muscle
fibres would help to achieve this goal.
Materials and Methods
Plasmids constructions
Expression vectors encoding HA and/or Flag tagged MAFbx wt
and MAFbx D-F-box, HA-tagged MRFs and HA-ubiquitin were
previously described [8,34]. ShRNAi sequence (shRNAi mouse
MAFbx, 59-GATCCCCCAGAAGATTCAACTACGTTTCAA-
GAGAACGTAGTTGATCTTCTGGTTTTTGGAAA-39) was
incorporated into 64 bp self-annealing oligonucleotides and cloned
into pTER+ expression vector (pTER+-MAFbx), (a gift of Van de
Wetering, Hubrecht Laboratory Center for Biomedical Genetics,
Utrecht, The Netherlands).
Cell culture and Transfections
The mouse skeletal muscle cell line C2C12 and the mouse
fibroblastic 10T1/2 cells ere grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 20% of fetal calf serum
(FCS) and antibiotics. Myoblast fusion and differentiation was
induced in subconfluent cells by replacing the medium with
DMEM 2% FCS. Primary cultures were prepared from male mice
from our own breeding stocks. All animals were treated in
accordance with institutional and national guidelines. Mice
satellite cells were isolated from the whole muscles of the
paw. Cells were plated at a density of 2610
4 cell/cm
2 on
Matrigel-coated Petri dishes (BD Biosciences), in 80% Ham’s-F10
medium containing glutamine, penicillin and amphotericin B
(Invitrogen), supplemented with 20% horse serum. After two days,
cells were washed with Ham’s-F10 and placed in complete
medium supplemented with 5 ng/mL basic fibroblast growth
factor. Atrophy was induced in cultured myotubes by switching
the medium to PBS (100 mM NaCl, 5 mM KCl, 1.5 mM
MgSO4, 50 mM NaHCO3, 1 mM NaH2PO4, 2 mM CaCl2)
for 6 hours. Primary cultures of satellite cells were transfected
with 2 mg of total plasmid using Dreamfect (OZBiosciences).
C2C12 myoblasts were cultured in 36-mm dishes and trans-
fected with 3 mg of total plasmid by using Lipofectamin
2000 (Invitrogen). High-level transfection efficiency for C2C12
myoblasts was achieved by using a modified protocol for
Lipofectamin 2000. Freshly trypsinized myoblasts were transfected
30 min after plating (300610
3 cells/36-mm dish) with a 2:1
ratio (ml/ mg) of Lipofectamin 2000 (10 ml/36-mm dish) to
plasmid DNA (5 mg/36-mm dish). An expression vector coding
for the GFP protein was transfected as control of transfection
efficacy.
Immunoprecipitation and immunoblotting
An anti-MAFbx antibody was generated by injecting rabbits
with a GST-MAFbx fusion protein corresponding to aa 1–102 of
the human MAFbx protein. Antibodies were affinity purified
against an MBP-MAFbx fusion protein. Myotubes were rinsed in
cold PBS and lysed in IP buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 10% glycerol, 0.5% NP40, 0.5 mM Na-orthovanadate,
50 mM NaF, 80 mM b-glycerophosphate, 10 mM Na-pyrophos-
phate, 1 mM DTT, 1 mM EGTA and 10 mg/ml leupeptin,
10 mg/ml pepstatin and 10 mg/ml aprotinin). Lysates were
precleaned for 30 min with protein-G beads and immunoprecip-
itated by using standard procedures. Immunoprecipitated proteins
were loaded onto 10% SDS/PAGE gels before electrophoretic
transfer onto nitrocellulose membrane. For detection of MyoD-
ubiquitin conjugates, cells were rinsed in phosphate buffer saline
and scrapped in RIPA buffer (20 mM Tris, pH 7.5, 5 mM EDTA,
150 mM NaCl, 1% NP40, 0.5% Na-deoxycholate, 0.025% SDS,
1 mMNa-orthovanadate, 10 mM NaF, 25 mM b-glycerophos-
phate and 1 mM leupeptin, 1 mM pepstatin and 10 mM aprotinin).
Cells were then spun at 150006g for 15 min and the supernatant
was precipitated with anti-MyoD antibody. Western blotting was
performed by using an ECL kit (Amersham) according to the
manufacturer’s instructions. Anti MyoD polyclonal (C20) was
purchased from Santa Cruz Biotechnology, Anti-Troponin T
monoclonal (JLT-12) and anti-tropomyosin (TM 311) were from
Sigma, anti-HA epitope (12CA5) was purchased from Roche, anti-
MyoD monoclonal (5.8A) and anti-myogenin (F5D) were from
Pharmingen and anti-Flag (M2) was from Sigma. To inhibit
proteasome activity, cells were treated with 30 mM of MG132
(Sigma) for 3 h.
Protein extraction for in vitro ubiquitination
C2C12 myotubes were suspended in 1,5 volume of ice-cold
buffer consisting of 25 mM Tris-HCl (pH 7.4), 2 mMDTT,
0,25 mM EDTA, 10 mg/ml leupeptin, 10 mg/ml pepstatin and
incubated in ice for 15 min. After addition of 0,2% Triton 6100
for 10 min the lysate was transferred to an Eppendorf tube and
centrifuged in a microcentrifuge at 10,000 g for 10 min. The
supernatant was divided into smaller samples and frozen at
280uC.
In vitro and in vivo ubiquitination assay
Ubiquitination assays were determined by using (
35S) methio-
nine–labelled in vitro translated MyoD [8,35]
RNA extraction and RT-PCR analyses
Total RNA was isolated from C2C12 cells using TRI REAGENT
(Sigma). For semi quantitative RT-PCR analysis, 1 mg of RNA was
used to perform reverse transcription with Superscript II RNaseH
Reverse Transcriptase and oligodT (Invitrogen). Two microliters of
each reaction served as a template for PCR analysis. Primer pairs for
the amplification of the gene products were the following: MAFbx 59-
GGGGGAAGCTTTCAACAG-39 forward, 59TGAGGCCTTT-
GAAGGCAG-39 reverse, MyoD 59-CCCGGCGGCAGAATGGC-
TACG-39forward, 59-GGTCTGGGTTCCCTGTTCTGTG-39 re-
verse and GAPDH 59-GAGCTGAACGGGAAGCTCACT-39
forward, 59-TTGTCATACCAGGAAATGAGC-39 reverse.
Figure 6. Expression of MyoD K133R in normal and fasted muscle fibres induces hypertrophy. A/ Representative cross-sectional areas of
electroporated TA muscles from fed and starved mice. Adult Tibialis anterior (TA) muscles were electroporated with either a control (GFP), a MyoDwt-
GFP or a MyoD mutant K133R-GFP plasmid. Mice (control or fasted by 2 days) were sacrificed 14 days later. Transfected fibres were identified on the
basis of their GFP expression. The distribution of cross-sectional areas of EGFP-expressing fibres taken from four muscles under each conditions Fibres
membranes were stained with polyclonal anti-laminin antibody. Scale bar, 20 mm. B/. Mean cross-sectional area of TA fibres in control (fed) and fasted
mice (atrophy)6s.e.m. *P,0.05 between control and MyoDwt or MyoD K133R electrotransferred fibres. # P,0,05 between MyoDwt and MyoD
K133R. n.200 fibres. C/. Histogram shows the fibre size distribution of TA from four mice per expression vector (in control: fed and atrophy: fasted
mice). Blue bars, empty vector, green bars MyoDwt and yellow bars mutant MyoD K133R.
doi:10.1371/journal.pone.0004973.g006
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Cells were cultured on coverslips and fixed in 3% Para
formaldehyde for 30 min at 4uC, and permeabilized with 0.5%
Triton X-100 for 30 min at room temperature. The cells were
treated with 5% normal goat serum and immunostained with the
mAb anti-MyoD (5.A8) and/or the polyclonal anti-MyoD (C-20),
anti-myogenin (F5D) and/or the purified anti-MAFbx. The Texas
red-conjugated F (ab’)2 fragments of donkey anti-mouse IgG were
used to visualize the mouse monoclonal antibodies and the FITC-
conjugated F(ab’)2. Fragments of Donkey anti-rabbit IgG to
visualize the rabbit polyclonal antibodies.
Cells were rinsed in PBS containing DAPI (Sigma), mounted in
citifluor and then were examined on a phase-contrast microscope
Axioplan 135 M; Zeiss with a 406 oil immersion objective at
room temperature. Images were captured with a camera model
(Axiocam HRc, Zeiss) using Axiovision software Rel.4, Zeiss) and
Photoshop 8.0 (Adobe).
Confocal microscopy was performed with primary mouse
skeletal muscle myoblasts. Cells grown on polylysine-coated cover
lips were fixed in 3% paraformaldehyde/2% sucrose in PBS at
pH 7.4 for 15–20 minutes at 37uC. After three washes in PBS,
cells were permeabilized using 0.2% Triton X-100 in PBS for
5 minutes at room temperature. Covers lips were rinsed three
times with PBS and incubated for 1 h at room temperature with
the indicated primary antibody diluted in PBS containing 1% BSA
and 1% goat serum. After three washes in PBS, the appropriate
secondary antibody was used. Myosin heavy chain (MHC) was
detected using a mouse monoclonal anti-MHC (My32)from
Sigma) and stained with anti mouse Texas-Red (Jackson
Immunoresearch Inc. (West Grove, PA). DNA was counterstained
with 1 mgm l
21 TOPRO-3 (Molecular Probes). Covers lips were
then inverted into Vectashield medium (Vector Lab. Burlingare,
CA). Images were acquired on a laser confocal microscope Zeiss
LSM 510 Meta system with a 406objective and processed with
Image VisArt and Photoshop 8 (Adobe).
Muscle electro transfer
Ethical approval was obtained for the use of animals in our study
(Ministe `re de l’Enseignement supe ´rieur et de la Recherche , Nu
4962, 12/03/2008) .All animals experiments were performed
according to European directives (86/609/CEE). In vivo transfec-
tion experiments were carried out on four 8-week-old C57BL/6
females. Mice were first anesthetized with isoflurane (0,75% to 1%
in oxygen) and received a single injection of 0,4 U of bovine
hyaluronidase (SIGMA)/ml in 25 ml 0,9% NaCl into the Tibialis
anterior (TA) muscle. 2 hours after, a total of 15 mg of plasmid
DNA in 0,9% NaCl was injected into the TA under conditions of
ketamine (100 mg/g of body weight) and xylazine (10 mg/g)
anaesthesia. pCMV-EGFP was used as a control and injected in
the left leg while pCMV-EGFP-MyoDwt or pCMV-EGFP-MyoD
K133R was injected in the contra lateral muscle. An electrical field
was then applied to muscle with calliper rule electrodes coated with
ultrasound transmission gel (Aquasonic 100, Parker) and placed on
each side of the leg. Six square-wave 130 V/cm pulses, lasting
60 ms each with a 100 ms interval, were then applied with a BTX
electrocell manipulator. Mice were killed by cervical dislocation,
and muscles were collected 14 days after electro transfer.
Histological analysis and fibre measurement
Fasted (48 h) and control (fed) C57BL/6 mice were killed by
cervical dislocation. Tibialis Anterior (TA) muscles were removed,
embedded in cryomatrix and quickly frozen in isopentane cooled
with liquid nitrogen. Muscles were then sectioned in a microtome
cryostat (Leica). Transversal sections (12 mm) were fixed with
methanol for 5 min at 220uC, rinsed three times with PBS,
permeabilized with 0.1% Triton X-100 and blocking 1 h (3%
BSA, 20% NGS in PBS). Rabbit polyclonal anti-Laminin antibody
(Sigma) was applied overnight to the treated sections. Bound
primary antibodies were detected with cyanine 3-conjugated goat
anti-rabbit Texas Red IgG (Jackson Immunoresearch). Nuclei
were stained with Hoechst. Fibre cross-sectional areas were
measured using Perfect Image software and determined for 4
sections from our animals in each group.
Statistics
All data are expressed as the mean6SEM. Data were evaluated
by one way analysis of variance (ANOVA) followed by Tukey’s
Honestly Significant Differences test (SigmaSTAT Software). A P-
value of ,0.05 was considered statistically significant.
Supporting Information
Figure S1 Specific interaction of MyoD with MAFbx. 10T1/2
fibroblastic cells were cotransfected with expression vectors
encoding HA-tagged MyoD, HA-tagged myogenin, HA-tagged
MRF4 or empty vector together with Flag-tagged MAFbx. Cells
were harvested 24 hr after transfection. Aliquots of total cell
extracts were directly probed with anti-HA and/or anti-Flag
antibodies (Inputs) and 400 mg of total proteins were immuno-
precipitated with anti-Flag antibodies prior to Western blotting
with anti-HA and anti-Flag antibodies respectively (IP).* non
specific band.
Found at: doi:10.1371/journal.pone.0004973.s001 (1.88 MB
EPS)
Figure S2 Increase expression of MAFbx in myotubes under-
going atrophy. A/ Morphology of normal and atrophic C2C12
myotubes. Myotubes at day 4 of differentiation were treated with
225 mM H202 (9 h), 50 mM dexamethasone (24 h) and/or were
starved by removal of growth medium, amino acids and glucose
and incubated in PBS for 6 h (staved). Medium was replaced in
refed cultures for 15 h (Refed). (Magnifications are 6400). B/
Measurement of average myotubes diameter after treatments as
described in (A). Results are presented as the mean(n.100
myotubes per conditions) +/2SEM. C/Analysis of MAFbx and
MyoD mRNA expression by semi-quantitative RT-PCR. Myo-
tubes were treated with increasing concentrations of dexametha-
sone for 24 h (DEX, 1, 10 and 50 mM), or incubated either in PBS
for 6 h or in H2O2 (225 mM) for 4 h and 9 h respectively.
GAPDH expression was used as an internal control.
Found at: doi:10.1371/journal.pone.0004973.s002 (0.72 MB TIF)
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